关于最近五年不存在被证券监管部门和证券交易所处罚 或采取监管措施的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 厦门特宝生物工程股份有限公司（以下简称"公司"）自上市以来，严格按照 《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所科创板股 票上市规则》等法律、法规、规范性文件及《厦门特宝生物工程股份有限公司章程》 的相关要求规范运作，不断完善法人治理结构，建立健全内部控制制度，促进公司 持续健康发展。鉴于公司已于 2026 年 1 月 26 日召开第九届董事会第十六次会议， 审议通过关于向不特定对象发行可转换公司债券的相关议案，根据相关要求，公司 对最近五年是否存在被证券监管部门和证券交易所处罚或采取监管措施的情况进行 了自查，自查结果如下： 证券代码：688278 证券简称：特宝生物 公告编号：2026-005 厦门特宝生物工程股份有限公司 特此公告。 厦门特宝生物工程股份有限公司 董事会 2026 年 1 月 27 日 经自查，公司最近五年不存在被证券监管部门和证券交易所处罚或采取监管措 施的情况 ...

证券代码：688278 证券简称：特宝生物 公告编号：2026-007 厦门特宝生物工程股份有限公司 关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2026年第一次临时股东会 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 等有关规定执行。 （四） 现场会议召开的日期、时间和地点 召开日期时间：2026 年 2 月 11 日 14 点 00 分 召开地点：厦门市海沧新阳工业区翁角路 330 号公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2026 年 2 月 11 日 至2026 年 2 月 11 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30， ...

证券代码：688278 证券简称：特宝生物 公告编号：2026-002 厦门特宝生物工程股份有限公司 第九届董事会第十六次会议决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 厦门特宝生物工程股份有限公司（以下简称"公司"）第九届董事会第十六次 会议于 2026 年 1 月 26 日以现场会议结合通讯表决的方式召开。本次会议已于 2026 年 1 月 16 日通过邮件方式通知公司全体董事。本次会议由董事长孙黎先生主持，会 议应出席董事 9 名，实际出席董事 9 名，董事会秘书及其他高级管理人员列席本次 会议。本次会议的召集和召开程序符合《公司法》和《公司章程》等有关规定，会 议决议合法、有效。 二、董事会会议审议情况 （一）审议通过《关于公司符合向不特定对象发行可转换公司债券条件的议案》 根据《公司法》《证券法》以及《上市公司证券发行注册管理办法》等有关法 律、法规及规范性文件的规定，董事会对公司的实际情况进行了逐项自查和论证， 认为公司符合现行法律、法规和规范性文件中关于科创板上市公司向不特 ...

每经头条（nbdtoutiao）——国际金价冲破5000美元！7年涨了280%，什么时候才见顶？专家：关键还 看美元，重点关注国际货币体系、降息和科技革命 （记者 曾健辉） 每经AI快讯，通化东宝1月26日晚间发布业绩预告，预计2025年年度实现归属于母公司所有者的净利润 约为12.42亿元，与上年同期相比，将实现扭亏为盈。业绩变动主要原因是，主营业务影响。国内市场 方面，公司依托本次胰岛素集采中标优势，推动门冬、甘精等胰岛素类似物产品快速上量，市场份额迅 速提升；同时，利拉鲁肽注射液与恩格列净片等产品同样取得良好增长，多品类协同发力，带动国内销 售收入较上期大幅攀升。公司国际化战略成效显著，出口收入增长明显。非经营性损益的影响。公司转 让厦门特宝生物工程股份有限公司股权产生收益，导致净利润大幅增加。 ...

Group 1 - The core transaction of Te Bao Bio occurred on January 22, with a volume of 91,000 shares and a transaction amount of 6.9533 million yuan, at a price of 76.41 yuan per share [2][4] - In the last three months, Te Bao Bio has recorded a total of 7 block trades, amounting to 57.4718 million yuan [3] - The closing price of Te Bao Bio on the day of the transaction was 76.41 yuan, reflecting a decrease of 2.20%, with a daily turnover rate of 0.52% and a total transaction amount of 163 million yuan [3] Group 2 - The latest margin financing balance for Te Bao Bio is 1.373 billion yuan, with a decrease of 8.1317 million yuan over the past five days, representing a decline of 0.59% [4] - The company, Xiamen Te Bao Bioengineering Co., Ltd., was established on August 7, 1996, with a registered capital of 4.0818948 billion yuan [4]

Group 1 - The core transaction involved 91,000 shares of TEBIO, with a total transaction value of 6.9533 million yuan, representing 4.1% of the total trading volume for the day [1][2] - The transaction price was 76.41 yuan, which was consistent with the market closing price on that day [1][2]

Core Viewpoint - The recent surge in the stock price of Changchun High-tech (000661.SZ) is attributed to the announcement of a new drug, GenSci141 ointment, aimed at treating a sensitive condition in children, which has sparked investor interest reminiscent of past successes with growth hormone products [1][2][4][6][9]. Group 1: Stock Performance and Market Reaction - From January 5 to January 12, 2025, Changchun High-tech's stock experienced a price increase of 5.79% with a trading range of 9.35% [1][2]. - As of January 22, 2025, the stock price fell by 0.19% to 97.50 CNY per share, with a total market capitalization of 39.77 billion CNY [2][23]. - The stock price did not return to its initial level after the surge, indicating some sustained interest despite the subsequent decline [1][2]. Group 2: Product Details and Market Expectations - GenSci141 ointment is a topical hormone treatment for children with a specific condition related to low testosterone signaling, aiming to provide a new therapeutic option [6][28]. - The unique positioning of the drug has led to significant speculation among investors, with discussions about its potential consumer market appeal and possible expansion of its target demographic [29]. - The condition targeted by GenSci141 is rare, with an incidence rate of approximately 0.0015% in the U.S. and 0.14% reported in Zhengzhou, China [29]. Group 3: Historical Context and Business Strategy - Changchun High-tech previously achieved significant success with growth hormone products, establishing a near-monopoly and reaching a market capitalization of over 210 billion CNY [10][32]. - The company has faced challenges since 2022 due to price reductions from centralized procurement and increased competition, leading to a decline in revenue and profit margins [10][34]. - The management has shifted focus towards innovative drug development, with expectations of surpassing 1 billion CNY in revenue from new products by 2025 [36][15]. Group 4: Financial Performance and Challenges - In 2024, the company reported its first negative revenue growth in nearly two decades, with a 43.01% year-over-year decline in net profit [10][34]. - For the first three quarters of 2025, net profit decreased by 58.23%, with a significant drop of 82.98% in the third quarter alone [10][34]. - The company has increased its R&D spending to support its innovation pipeline, with a 17.32% year-over-year increase in R&D investment [15][36]. Group 5: Future Prospects and Risks - The success of GenSci141 and other innovative products is critical for the company to overcome the decline in its core growth hormone business [17][40]. - The company is exploring a listing on the Hong Kong stock exchange to alleviate cash flow pressures and support international expansion [40]. - There are concerns regarding the sustainability of its business model and the potential for regulatory challenges in the current healthcare environment [41].

Core Viewpoint - The A-share market experienced fluctuations on January 22, with the Shanghai Composite Index rising by 0.14%. The innovative drug sector faced pressure, as evidenced by the decline of the Science and Technology Innovation Drug ETF Huatai (589120) by 1.51% by 15:00. However, the ETF saw a net inflow of funds totaling 27.7361 million yuan over the past three days, indicating a trend of buying on dips [1]. Group 1: Market Performance - The Science and Technology Innovation Drug ETF Huatai (589120) recorded a net inflow of 27.7361 million yuan over three days, showing a clear trend of increased buying despite market declines [1]. - By 15:00, the ETF's component stocks exhibited mixed performance, with notable gains from Kangxinuo at 1.81%, Baiaotai at 0.49%, and Haoyuan Pharmaceutical at 0.48%. Conversely, Yifang Bio fell over 6%, Rongchang Bio dropped over 4%, and Baili Tianheng decreased by over 3% [6]. Group 2: Industry Insights - According to the National Medical Insurance Administration, 76 innovative drugs are expected to be approved for market entry by the National Medical Products Administration by 2025, marking a record high and indicating a trend towards diversified innovative therapies in China [4]. - Donghai Securities predicts that the innovative drug sector is entering a new era, transitioning from a generics-dominated market (pre-2018) to a period of transformation (2018-2025) characterized by price reductions and increased R&D investments in innovative drugs. By 2026, innovative drugs are expected to dominate the pharmaceutical industry in China, supported by complementary insurance policies and a focus on the pace of new drug launches and competitive dynamics [5].

Group 1 - The biopharmaceutical sector increased by 0.19% on January 21, with Nearshore Protein leading the gains [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] - Key stocks in the biopharmaceutical sector showed significant price increases, with Nearshore Protein rising by 6.37% to a closing price of 48.76 [1] Group 2 - The biopharmaceutical sector experienced a net inflow of 77.04 million yuan from institutional investors, while retail investors saw a net outflow of 284 million yuan [2] - Major stocks like Watson Bio and Ganli Pharmaceutical attracted significant institutional investment, with net inflows of 64.45 million yuan and 55.25 million yuan, respectively [3] - Retail investors showed a negative trend in several stocks, with Watson Bio and Ganli Pharmaceutical experiencing net outflows of 33.30 million yuan and 39.14 million yuan, respectively [3]

Group 1 - The core viewpoint of the news highlights the growth of the biomedical sector in China's STAR Market, with the STAR Market Biomedical Index rising by 0.29% and specific stocks like Tianzhihang increasing by 14.64% [1] - The National Healthcare Security Administration has released a guideline for pricing surgical and treatment auxiliary medical services, establishing a fee framework for innovative technologies such as surgical robots and remote surgeries, promoting a coefficient-based charging model linked to robotic assistance [1] - Guohai Securities points out that artificial intelligence is accelerating the empowerment of the entire pharmaceutical industry chain, with NVIDIA and Eli Lilly announcing a joint AI innovation lab, investing up to $1 billion over five years to explore AI applications in drug discovery, development, and manufacturing [1] Group 2 - As of December 31, 2025, the top ten weighted stocks in the STAR Market Biomedical Index include companies like United Imaging Healthcare and BeiGene, collectively accounting for 48.85% of the index [1] - The STAR Market Medical ETF by Harvest (588700) closely tracks the STAR Market Biomedical Index, providing an easy investment opportunity in the biomedical sector for investors without stock accounts through the Harvest Medical ETF linked fund (021061) [2]